Recent advances in autoimmune autonomic ganglionopathy

Nicole Winston, Steven Vernino

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose of review: This review highlights recent advances in our understanding of autoimmune autonomic ganglionopathy (AAG) including serological diagnosis, clinical observations, pathophysiology, and treatment. Recent findings: Classical AAG is a subacute disorder associated with antibodies against ganglionic acetylcholine receptors. Recent observations demonstrate that these antibodies cause a specific inhibition of synaptic transmission in autonomic ganglia and antibody levels correlate in a predictable way with severity of autonomic failure. Ganglionic acetylcholine receptor antibodies can be associated with other neurological disorders including chronic or restricted forms of autonomic dysfunction and with neurological or paraneoplastic disorders unrelated to the autonomic nervous system. Treatment of AAG is based on case reports. It is clear that AAG patients respond to immunomodulatory treatments but combination immunotherapy may be required to achieve a clinical response. Recently, additional clinical observations indicate that AAG patients may also show signs of treatment-responsive cognitive impairment. Summary: The pathophysiology and varied clinical presentation of AAG are becoming more clear. AAG is a treatable antibody-mediated disorder of autonomic ganglionic synaptic transmission. Future studies will continue to define the optimal diagnostic and therapeutic approach to autoimmune autonomic disorders.

Original languageEnglish (US)
Pages (from-to)514-518
Number of pages5
JournalCurrent Opinion in Neurology
Volume23
Issue number5
DOIs
StatePublished - Oct 2010

Fingerprint

Antibodies
Cholinergic Receptors
Synaptic Transmission
Autonomic Ganglia
Therapeutics
Autonomic Nervous System
Nervous System Diseases
Immunotherapy
Inhibition (Psychology)
Cognitive Dysfunction

Keywords

  • acetylcholine receptor
  • antibodies
  • orthostatic hypotension
  • synaptic transmission

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Recent advances in autoimmune autonomic ganglionopathy. / Winston, Nicole; Vernino, Steven.

In: Current Opinion in Neurology, Vol. 23, No. 5, 10.2010, p. 514-518.

Research output: Contribution to journalArticle

@article{e611f1f34d0f47838dcb56a9b0f14df7,
title = "Recent advances in autoimmune autonomic ganglionopathy",
abstract = "Purpose of review: This review highlights recent advances in our understanding of autoimmune autonomic ganglionopathy (AAG) including serological diagnosis, clinical observations, pathophysiology, and treatment. Recent findings: Classical AAG is a subacute disorder associated with antibodies against ganglionic acetylcholine receptors. Recent observations demonstrate that these antibodies cause a specific inhibition of synaptic transmission in autonomic ganglia and antibody levels correlate in a predictable way with severity of autonomic failure. Ganglionic acetylcholine receptor antibodies can be associated with other neurological disorders including chronic or restricted forms of autonomic dysfunction and with neurological or paraneoplastic disorders unrelated to the autonomic nervous system. Treatment of AAG is based on case reports. It is clear that AAG patients respond to immunomodulatory treatments but combination immunotherapy may be required to achieve a clinical response. Recently, additional clinical observations indicate that AAG patients may also show signs of treatment-responsive cognitive impairment. Summary: The pathophysiology and varied clinical presentation of AAG are becoming more clear. AAG is a treatable antibody-mediated disorder of autonomic ganglionic synaptic transmission. Future studies will continue to define the optimal diagnostic and therapeutic approach to autoimmune autonomic disorders.",
keywords = "acetylcholine receptor, antibodies, orthostatic hypotension, synaptic transmission",
author = "Nicole Winston and Steven Vernino",
year = "2010",
month = "10",
doi = "10.1097/WCO.0b013e32833d4c7f",
language = "English (US)",
volume = "23",
pages = "514--518",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Recent advances in autoimmune autonomic ganglionopathy

AU - Winston, Nicole

AU - Vernino, Steven

PY - 2010/10

Y1 - 2010/10

N2 - Purpose of review: This review highlights recent advances in our understanding of autoimmune autonomic ganglionopathy (AAG) including serological diagnosis, clinical observations, pathophysiology, and treatment. Recent findings: Classical AAG is a subacute disorder associated with antibodies against ganglionic acetylcholine receptors. Recent observations demonstrate that these antibodies cause a specific inhibition of synaptic transmission in autonomic ganglia and antibody levels correlate in a predictable way with severity of autonomic failure. Ganglionic acetylcholine receptor antibodies can be associated with other neurological disorders including chronic or restricted forms of autonomic dysfunction and with neurological or paraneoplastic disorders unrelated to the autonomic nervous system. Treatment of AAG is based on case reports. It is clear that AAG patients respond to immunomodulatory treatments but combination immunotherapy may be required to achieve a clinical response. Recently, additional clinical observations indicate that AAG patients may also show signs of treatment-responsive cognitive impairment. Summary: The pathophysiology and varied clinical presentation of AAG are becoming more clear. AAG is a treatable antibody-mediated disorder of autonomic ganglionic synaptic transmission. Future studies will continue to define the optimal diagnostic and therapeutic approach to autoimmune autonomic disorders.

AB - Purpose of review: This review highlights recent advances in our understanding of autoimmune autonomic ganglionopathy (AAG) including serological diagnosis, clinical observations, pathophysiology, and treatment. Recent findings: Classical AAG is a subacute disorder associated with antibodies against ganglionic acetylcholine receptors. Recent observations demonstrate that these antibodies cause a specific inhibition of synaptic transmission in autonomic ganglia and antibody levels correlate in a predictable way with severity of autonomic failure. Ganglionic acetylcholine receptor antibodies can be associated with other neurological disorders including chronic or restricted forms of autonomic dysfunction and with neurological or paraneoplastic disorders unrelated to the autonomic nervous system. Treatment of AAG is based on case reports. It is clear that AAG patients respond to immunomodulatory treatments but combination immunotherapy may be required to achieve a clinical response. Recently, additional clinical observations indicate that AAG patients may also show signs of treatment-responsive cognitive impairment. Summary: The pathophysiology and varied clinical presentation of AAG are becoming more clear. AAG is a treatable antibody-mediated disorder of autonomic ganglionic synaptic transmission. Future studies will continue to define the optimal diagnostic and therapeutic approach to autoimmune autonomic disorders.

KW - acetylcholine receptor

KW - antibodies

KW - orthostatic hypotension

KW - synaptic transmission

UR - http://www.scopus.com/inward/record.url?scp=77956395081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956395081&partnerID=8YFLogxK

U2 - 10.1097/WCO.0b013e32833d4c7f

DO - 10.1097/WCO.0b013e32833d4c7f

M3 - Article

C2 - 20634694

AN - SCOPUS:77956395081

VL - 23

SP - 514

EP - 518

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 5

ER -